Search

Dyslipidemia (DLP) and Heart Failure (HF) are growing diseases worldwide. Patients with cardiometabolic risk factors such as Non-Alcoholic Fatty Liver Disease (NAFLD) are at increased risk for adverse outcomes. Nevertheless, there is limited scientific evidence of clinical outcomes of NAFLD in patients with DLP and HF. We aimed to investigate clinical outcomes and resource utilization in patients with DLP and HF affected by NAFLD. We queried NIS between 2017-2020 for adult patients who were hospitalized with DLP and HF and had NAFLD. The primary outcome was inpatient mortality. The secondary outcomes were cardiogenic shock, cardiac arrest, gastrointestinal bleeding (GIB), intubation, length of stay (LOS), and total hospital charge. Multivariable logistic and Poisson regression analyses were used to estimate clinical outcomes. P-value < 0.05 was significant. There were 11,328,309 hospitalizations with DLP and HF and 364,545 (3.2%) had NAFLD. NAFLD and non-NAFLD cohorts were with mean age of 69.6 vs 73 yrs; males 56.1% vs 52.5%; Caucasians 67.4% vs 69.7%; pulmonary hypertension (PH) 17.9% vs 14.4%; PE 3.8% vs 4.7%; DM 62.8% vs 54.5%; PVD 4.9% vs 6.2%; AF 44.9% vs 44.5%; CKD 54.6% vs 47.7%; hemodialysis 9.2% vs 6.4%; obesity 27% vs 26%; anemia 9.6% vs 6.9%; ACS 17.3% vs 14.4%; history of MI 16% vs 18.9%; stroke 2% vs 2.9%, COPD 33.3% vs 35%; alcohol use 6.1% vs 2.7%, respectively. NAFLD cohort had significantly higher mortality and worse clinical outcomes (Table 1). DLP and HF group demonstrated significantly higher mortality, worse clinical outcomes, and resource utilization. Patients were younger, male, with more frequent PH, DM, AF, CKD, hemodialysis, obesity, anemia, ACS and alcohol use. NAFLD shows association with metabolic syndrome, renal and cardiac dysfunction. Early identification of NAFLD in patients with DLP and HF is beneficial to improve outcomes. Further research is necessary to describe long-term outcomes in this population. No [ABSTRACT FROM AUTHOR]

Dyslipidemia (DLP) and chronic kidney disease (CKD) are global diseases affecting millions worldwide. Non-Alcoholic Fatty Liver Disease (NAFLD) is an emerging disease that predisposes to adverse outcomes. Nevertheless, there is limited scientific evidence of clinical outcomes of NAFLD in patients with DLP & CKD. We sought to investigate clinical outcomes and resource utilization in population with DLP & CKD affected by NAFLD. We queried NIS between 2017-2020 for adult patients who were hospitalized with DLP & CKD and had NAFLD. The primary outcome was inpatient mortality. The secondary outcomes were cardiogenic shock, cardiac arrest, gastrointestinal bleeding (GIB), acute kidney injury (AKI), invasive mechanical ventilation, length of stay (LOS) and total hospital charge. Multivariable logistic, linear and Poisson regression analyses were used to estimate clinical outcomes. P-value < 0.05 was significant. There were 11,116,540 hospitalizations with DLP & CKD and 366,290 (3.2%) had NAFLD. NAFLD and non-NAFLD cohorts were with mean age of 69.4 vs. 72.6 yrs; males 55.6% vs 54.4%; Caucasians 63.0% vs 65.2%; HF 54.4% vs 48.7%; pulmonary hypertension (PH) 13.0% vs 9.6%; PE 3% vs 4%; DM 69.6% vs 60.9%; AF 34.6% vs 32.7%; AKI 53.7% vs 42.3%; requiring hemodialysis 16.4% vs 13.3%; obesity 24.7% vs 23.7%; anemia 25.0% vs 20.5%; ACS 12.3% vs 11.0%; history of MI 12.5% vs 14.5%; stroke 1.9% vs 3.4%, COPD 25.4% vs 26.2%; alcohol use 5.2% vs 1.9%, respectively. NAFLD cohort had significantly higher mortality and worse clinical outcomes (Table 1). DLP & CKD group demonstrated significantly higher mortality, worse clinical outcomes and resource utilization. Patients were younger, male, predominantly Caucasian, with more frequent HF, PH, DM, AF, AKI, hemodialysis, obesity, anemia, ACS and alcohol use. NAFLD is associated with more profound cardiac and renal insufficiency, metabolic syndrome. Awareness of NALFD and its early identification is important to improve health outcomes. Further research is necessary to describe long-term outcomes in this population. No [ABSTRACT FROM AUTHOR]